CRBPCorbus Pharmaceuticals Hold...

Nasdaq corbuspharma.com


$ 53.01 $ -2.09 (-3.8 %)    

Tuesday, 06-Aug-2024 15:59:46 EDT
QQQ $ 437.58 $ 4.16 (0.96 %)
DIA $ 389.72 $ 3.15 (0.81 %)
SPY $ 522.63 $ 4.77 (0.92 %)
TLT $ 96.88 $ -2.21 (-2.24 %)
GLD $ 220.73 $ -1.78 (-0.8 %)
$ 52.94
$ 55.29
$ 52.75 x 104
-- x --
$ 52.65 - $ 58.90
$ 3.03 - $ 61.90
404,300
na
585.16M
$ 1.19
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-06-2024 06-30-2024 10-Q
2 05-07-2024 03-31-2024 10-Q
3 03-12-2024 12-31-2023 10-K
4 11-07-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 03-07-2023 12-31-2022 10-K
8 11-08-2022 09-30-2022 10-Q
9 08-09-2022 06-30-2022 10-Q
10 05-10-2022 03-31-2022 10-Q
11 03-08-2022 12-31-2021 10-K
12 11-12-2021 09-30-2021 10-Q
13 08-12-2021 06-30-2021 10-Q
14 05-13-2021 03-31-2021 10-Q
15 03-15-2021 12-31-2020 10-K
16 11-09-2020 09-30-2020 10-Q
17 08-06-2020 06-30-2020 10-Q
18 05-11-2020 03-31-2020 10-Q
19 03-16-2020 12-31-2019 10-K
20 11-07-2019 09-30-2019 10-Q
21 08-08-2019 06-30-2019 10-Q
22 05-09-2019 03-31-2019 10-Q
23 03-12-2019 12-31-2018 10-K
24 11-08-2018 09-30-2018 10-Q
25 08-08-2018 06-30-2018 10-Q
26 05-10-2018 03-31-2018 10-Q
27 03-12-2018 12-31-2017 10-K
28 11-08-2017 09-30-2017 10-Q
29 08-09-2017 06-30-2017 10-Q
30 05-09-2017 03-31-2017 10-Q
31 03-08-2017 12-31-2016 10-K
32 11-10-2016 09-30-2016 10-Q
33 08-12-2016 06-30-2016 10-Q
34 05-13-2016 03-31-2016 10-Q
35 03-28-2016 12-31-2015 10-K
36 11-10-2015 09-30-2015 10-Q
37 08-13-2015 06-30-2015 10-Q
38 05-13-2015 03-31-2015 10-Q
39 02-10-2015 12-31-2014 10-K
40 11-13-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 hc-wainwright--co-reiterates-buy-on-corbus-pharmaceuticals-maintains-80-price-target

HC Wainwright & Co. analyst Andrew Fein reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and maintains $80 pri...

 corbus-pharmaceuticals-q2-eps-090-beats-126-estimate

Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(0.90) per share which beat the analyst consensus estimate o...

 genedx-leads-russell-2000-this-year-as-it-shifts-to-more-comprehensive-genetic-testing-corrected

GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and r...

 genedx-leads-russell-2000-this-year-as-it-shifts-to-more-comprehensive-genetic-testing-corrected

GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and r...

 hc-wainwright--co-reinstates-buy-on-corbus-pharmaceuticals-announces-80-price-target

HC Wainwright & Co. analyst Andrew Fein reinstates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and announces $80 pri...

 oppenheimer-reiterates-outperform-on-corbus-pharmaceuticals-maintains-80-price-target

Oppenheimer analyst Jeff Jones reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and maintains $80 price tar...

 b-riley-securities-initiates-coverage-on-corbus-pharmaceuticals-with-buy-rating-announces-price-target-of-85

B. Riley Securities analyst Kalpit Patel initiates coverage on Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy rating and an...

 corbus-pharmaceuticals-board-member-to-sell-shares-in-planned-trading

In a recent move signaling strategic financial planning, Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) announced that Dr...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION